GSK CEO says restructuring plan expected to have limited impact in UK
GSK•GSK CEO Luke Miels said the restructuring plan is expected to have some limited impact in the UK. He also sees potential to grow Shingrix next year, while Q3 restructuring charges relate to streamlining support services.
1. Restructuring and business updates
GSK CEO Luke Miels said the restructuring plan is expected to have some limited impact in the UK. He said there is potential to grow Shingrix next year and that the cancer drug pipeline is progressing well in small cell lung cancer; CFO Julie Brown said Q3 restructuring charges relate to streamlining support services.
